Daniel is a member of our founding executive team and has served as our Chief Scientific Officer since March 2018. Previously, he was Executive Director and then promoted to Vice President of Biology at Inception Sciences, Inc., or Inception, a Versant Ventures discovery engine, from February 2011 to February 2018 where he led all aspects of biology and non-clinical pharmacology, including the acquisition of the remyelination program Inception 5 by Roche Holdings Inc. Prior to joining Inception, Dr. Lorrain was Senior Director of Pharmacology at Amira Pharmaceuticals, Inc. from July 2005 to November 2010 and contributed to the discovery of several clinical stage small molecule therapeutics to treat inflammation and fibrosis. Notably, he led the efforts of the LPA1R program that was acquired by Bristol Myers Squibb Company. Prior to that, he was a Research Fellow at Merck & Co., Inc. from November 1999 to June 2005 where he contributed to early central nervous system drug discovery.
Daniel received a B.S. in Psychology from the State University of New York at Buffalo in 1991 and a PhD in Behavioral Neuroscience from the State University of New York at Buffalo in 1997 and was a postdoctoral fellow at the University of Chicago from 1997 to 1999.
